|
Clinical characteristics of colorectal cancer patients and GSTT2 genotypes |
|||||||||||||||
| -537 G>A |
-277T>C |
-158G>A |
|||||||||||||
|
|
|||||||||||||||
| GG (%) |
GA (%) |
AA (%) |
p1 |
GA+AA (%) |
p2 |
TT (%) |
TC (%) |
CC (%) |
p1 |
TC+CC (%) |
p2 |
TT (%) |
TC (%) |
p2 |
|
|
|
|||||||||||||||
| No. of subjects |
127 |
240 |
69 |
309 |
388 |
45 |
3 |
48 |
416 |
20 |
|||||
| Age (years ± SD) |
59.1 ± 13.2 |
58.91 ± 13.0 |
57.9 ± 12.2 |
0.83 |
58.7 ± 12.8 |
0.76 |
58.6 ± 13.0 |
60.0 ± 11.7 |
66.5 ± 2.1 |
0.56 |
60.3 ± 11.5 |
0.41 |
58.8 ± 13.0 |
58.2 ± 11.7 |
0.85 |
| Sex (M/F) |
|||||||||||||||
| Male |
81 (64.8) |
151 (63.4) |
44 (63.8) |
0.97 |
195 (63.5) |
0.8 |
247 (64.2) |
27 (60.0) |
2 (100) |
0.49 |
29 (61.7) |
0.74 |
262 (63.4) |
14 (73.7) |
0.36 |
| Female |
44 (35.2) |
87 (36.6) |
25 (36.2) |
112 (36.5) |
138 (35.8) |
18 (40.0) |
- |
18 (38.3) |
151 (36.6) |
5 (26.3) |
|||||
| Location |
|||||||||||||||
| proxim al |
48 (39.3) |
84 (35.6) |
19 (29.7) |
0.43 |
103 (34.3) |
0.33 |
135 (36.0) |
15 (33.3) |
1 (50.0) |
0.86 |
16 (34.0) |
0.79 |
141 (35.0) |
10 (52.6) |
0.18 |
| distal |
74 (60.7) |
152 (64.4) |
45 (70.3) |
197 (65.7) |
240 (64.0) |
30 (66.7) |
1 (50.0) |
31 (66.0) |
262 (65.0) |
9 (47.4) |
|||||
| MSI status |
|||||||||||||||
| MSI |
17 (13.9) |
35 (14.8) |
10 (14.5) |
0.97 |
45 (14.8) |
0.83 |
52 (13.6) |
10 (23.8) |
- |
0.17 |
10 (22.7) |
0.1 |
59 (14.4) |
3 (17.6) |
0.71 |
| MSS |
105 (86.1) |
201 (85.2) |
59 (85.5) |
260 (85.2) |
331 (86.4) |
32 (76.2) |
2 (100) |
34 (77.3) |
351 (85.6) |
14 (82.4) |
|||||
| T-stage |
|||||||||||||||
| T1 |
- |
2 (0.9) |
2 (3.1) |
0.11 |
4 (1.3) |
0.39 |
4 (1.1) |
- |
- |
0.95 |
- |
0.74 |
4 (1.0) |
- |
0.9 |
| T2 |
8 (6.5) |
8 (3.4) |
2 (3.1) |
10 (3.3) |
15 (4.0) |
3 (6.8) |
- |
3 (6.5) |
17 (4.2) |
1 (5.3) |
|||||
| T3 |
102 (82.3) |
195 (83.0) |
56 (86.1) |
251 (83.4) |
317 (83.6) |
34 (77.3) |
2 (100) |
36 (78.3) |
336 (82.8) |
17 (89.5) |
|||||
| T4 |
14 (11.3) |
30 (12.8) |
5 (7.7) |
35 (11.6) |
42 (11.1) |
7 (15.9) |
- |
7 (15.2) |
48 (11.8) |
1 (5.3) |
|||||
| N-stage |
|||||||||||||||
| N0 |
58 (46.8) |
119 (50.4) |
35 (53.0) |
0.31 |
154 (51.0) |
0.54 |
189 (49.7) |
23 (52.3) |
- |
0.13 |
23 (50.0) |
0.55 |
200 (49.1) |
12 (63.2) |
0.38 |
| N1 |
36 (29.0) |
75 (31.8) |
14 (21.2) |
89 (29.5) |
114 (30.0) |
9 (20.5) |
2 (100) |
11 (23.9) |
122 (30.0) |
3 (15.8) |
|||||
| N2 |
30 (24.2) |
42 (17.8) |
17 (25.8) |
59 (19.5) |
77 (20.3) |
12 (27.3) |
- |
12 (26.1) |
85 (20.9) |
4 (21.1) |
|||||
| M-stage |
|||||||||||||||
| M0 |
90 (74.4) |
182 (78.1) |
52 (78.8) |
0.69 |
234 (78.3) |
0.39 |
293 (78.3) |
30 (68.2) |
1 (50.0) |
0.21 |
31 (67.4) |
0.1 |
311 (77.6) |
13 (68.4) |
0.35 |
| M1 |
31 (25.6) |
51 (21.9) |
14 (21.2) |
65 (21.7) |
81 (21.7) |
14 (31.8) |
1 (50.0) |
15 (32.6) |
90 (22.4) |
6 (31.6) |
|||||
| TNM stage |
|||||||||||||||
| I |
6 (5.0) |
10 (4.3) |
3 (4.6) |
0.94 |
13 (4.4) |
0.69 |
16 (4.3) |
3 (6.8) |
- |
0.37 |
3 (6.5) |
0.2 |
18 (4.5) |
1 (5.3) |
0.46 |
| II |
42 (34.7) |
93 (40.1) |
28 (43.1) |
121 (40.7) |
145 (39.0) |
18 (40.9) |
- |
18 (39.1) |
154 (38.6) |
9 (47.4) |
|||||
| III |
42 (34.7) |
78 (33.6) |
20 (30.8) |
98 (33.0) |
130 (34.9) |
9 (20.5) |
1 (50.0) |
10 (21.7) |
137 (34.3) |
3 (15.8) |
|||||
| IV |
31 (25.6) |
51 (22.0) |
14 (21.5) |
65 (21.9) |
81 (21.8) |
14 (31.8) |
1 (50.0) |
15 (32.6) |
90 (22.6) |
6 (31.6) |
|||||
|
Student's t-test or χ2 test; p1: Co-dominant model; p2: Dominant model | |||||||||||||||
Jang et al. BMC Cancer 2007 7:16 doi:10.1186/1471-2407-7-16 |
|||||||||||||||